Intuitive Surgical Stocks Fall 3.7% as Procedure Outlook Stays R
Intuitive Surgical (ISRG) reported Q3 revenue of $3.05B, with combined da Vinci and Ion procedures growing 15%. Shares fell 3.7% to $418.08. The company placed 546 da Vinci systems and expanded its installed base by 12%. A $450M antitrust-settlement charge impacted GAAP earnings.
How this was made
The 30-second read
Why it matters
The earnings release combines solid revenue growth with a sizable settlement charge and cautious guidance, creating short‑term downside risk.
Market read
The earnings miss and settlement charge are likely to weigh on ISRG and peer robotics‑surgery stocks.
What to watch
Potential upside from upcoming product upgrades and long‑term recurring instrument revenue.
Background
Intuitive Surgical is the market leader in robotic‑assisted surgery, with a large installed base that drives recurring revenue.
Ticker impact
Intuitive Surgical reported Q3 revenue of $3.05 B, a 15% rise in procedures and a $450 M antitrust settlement charge, while its stock fell 3.7% after the release.
downward pressure as investors price in the settlement charge and modest outlook
The company disclosed a sizable one‑time charge and a cautious procedure outlook, which typically weigh on near‑term price.
Market effects
Robotics‑surgery sector may see broader scrutiny on margins after the settlement charge.
U.S. healthcare stocks could face short‑term weakness.
Limited to companies with similar surgical‑robot business models.
Counterpoint
The 15% rise in procedures and expanding installed base could support a rebound if utilization accelerates.
Key entities
- CompanyIntuitive Surgical
Robotic‑surgery equipment manufacturer (ticker ISRG).
